Cooperation between ZEB2 and SP1 upregulates PD‑L1 and CCL2 to promote the immunosuppressive activity of tumor cells
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Zinc Finger E-Box Binding Homeobox 2 (ZEB2) confers immunosuppressive activity on cancer cells by upregulating PD-L1 and CCL2. This transcription factor modulates tumor-immune cell interactions and impacts patient survival, revealing a novel role in cancer progression.
Area Of Science
- Oncology
- Immunology
- Molecular Biology
Background
- Epithelial-mesenchymal transition (EMT) is crucial in tumor progression, with EMT-inducing transcription factors playing complex roles.
- ZEB2 was previously shown to promote cancer cell invasion, survival, and angiogenesis.
- The molecular mechanisms of EMT-inducing transcription factors, particularly their role in immune evasion, remain incompletely understood.
Purpose Of The Study
- To investigate the novel role of Zinc Finger E-Box Binding Homeobox 2 (ZEB2) in conferring immunosuppressive activity on cancer cells.
- To elucidate the molecular mechanisms by which ZEB2 influences the tumor microenvironment and immune cell function.
- To assess the clinical relevance of ZEB2 expression in relation to immune markers and patient prognosis.
Main Methods
- Co-culture systems to assess ZEB2-mediated effects on T cell activation and cytokine secretion.
- Syngeneic mouse tumor models to evaluate ZEB2's impact on tumor-infiltrating T cells.
- Analysis of promoter regions to identify ZEB2 binding sites and regulatory elements for target genes.
- Western blotting and co-immunoprecipitation to study protein interactions and SUMOylation.
- Correlation analysis of gene expression data from clinical samples.
Main Results
- ZEB2 cooperates with SP1 to upregulate the transcription of CD274 (PD-L1) and CCL2 by binding to SP1 elements in their promoters.
- ZEB2-induced PD-L1 expression on tumor cells inhibits T cell activation and cytokine secretion.
- ZEB2 promotes C-C motif chemokine ligand 2 (CCL2) secretion, enhancing macrophage migration and M2 polarization.
- ZEB2 suppresses the activity of tumor-infiltrating T cells in vivo.
- SUMOylation of ZEB2 by PC2 is essential for ZEB2/SP1 cooperation and downstream gene expression.
- Clinical data show positive correlations between ZEB2, CD274, and CCL2 expression.
- ZEB2 and CD274 or CBX4 expression are prognostic indicators for colon cancer patient survival.
Conclusions
- ZEB2 plays a significant role in establishing an immunosuppressive tumor microenvironment.
- ZEB2 directly modulates tumor-immune cell interactions by regulating PD-L1 and CCL2.
- ZEB2's function is dependent on its SUMOylation and cooperation with SP1.
- ZEB2 represents a potential therapeutic target for enhancing anti-tumor immunity.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.